Advanced search
Publication Cover
Clinical Toxicology Volume 57, 2019 - Issue 2
Submit an article Journal homepage
1,019
Views
3
CrossRef citations to date
0
Altmetric
Clinical Research

Physiologically based pharmacokinetic modelling of acute digoxin toxicity and the effect of digoxin-specific antibody fragments

Lucy M. BrackenPharmacology, Sydney Medical School, University of Sydney, Sydney, Australia; ;Department of Emergency Medicine, Clinical Toxicology Unit, Prince of Wales Hospital, New South Wales, Australia; ORCID Iconhttp://orcid.org/0000-0002-2734-9347View further author information
ORCID Icon,
Betty S. H. ChanDepartment of Emergency Medicine, Clinical Toxicology Unit, Prince of Wales Hospital, New South Wales, Australia; ;New South Wales Poisons Information Centre, New South Wales, AustraliaORCID Iconhttp://orcid.org/0000-0003-0083-282XView further author information
ORCID Icon &
Nicholas A. BuckleyPharmacology, Sydney Medical School, University of Sydney, Sydney, Australia; ;New South Wales Poisons Information Centre, New South Wales, AustraliaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-6326-4711View further author information
ORCID Icon
Pages 117-124 | Received 30 Oct 2017, Accepted 17 Jul 2018, Published online: 11 Oct 2018

References

  • Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med. 2008;36:3014–3018.
  • Pincus M. Management of digoxin toxicity. Aust Prescr. 2016;39:18–20.
  • Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27:1115–1133.
  • U.S. Food and Drug Administration[internet]. Prescribing information for Digoxin Oral Solution. 2011; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021648s004lbl.pdf.
  • Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet. 1995;28:483–493.
  • Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014;52:824–836.
  • Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol. 2015;79:48–55.
  • Yukawa E, Suematu F, Yukawa M, et al. Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. Clinical Pharmacokinetics. 2001;40:773–781.
  • Zhao P, Rowland M, Huang SM. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther. 2012;92:17–20.
  • Ozgür B, Saaby L, Langthaler K, et al. Data demonstrating the challenges of determining the kinetic parameters of P-gp mediated transport of low-water soluble substrates. Data Brief. 2018;16:655–659.
  • Wood JH, Thakker KM. Michaelis-Menten absorption kinetics in drugs: - examples and implications. Eur J Clin Pharmacol. 1982;23:183–188.
  • Zhao Y, Hu Z-Y. Physiologically based pharmacokinetic modelling and in vivo [I]/Ki accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. Br J Pharmacol. 2014;171:1043–1053.
  • Jones HM, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT: Pharmacomet Syst Pharmacol. 2013;2:e63.
  • Chan BS, Isbister GK, O’Leary M, et al. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Clin Toxicol (Phila). 2016;54:488–494.
  • Neuhoff S, Yeo KR, Barter Z, et al. Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. J Pharm Sci. 2013;102:3145–3160.
  • Winter ME, Boro MS. Basic clinical pharmacokinetics. Philadelphia: Wolters Kluwer; 2009. p. 203.
  • Davis RE, Kelsall RA, Stenhouse NS, et al. 'Normal' haematological values in Western Australia. Pathology. 1971;3:72–73.,
  • Schaumann W, Kaufmann B, Neubert P, et al. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol. 1986;30:527–533.
  • Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016;6:430–440.
  • Rowland, M, Tozer, T.N. Clinical pharmacokinetics 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1994.
  • Andersson, KE, Bertler, A, Wettrell, G. Post-mortem distribution and tissue concentrations of digoxin in infants and adults. Acta Paediatr Scand. 1975;64(3):497-504.
  • Delp, M. Physiological parameter values for PBPK models. International Life Sciences Institute; 1994.
  • Peters, SA, Appendices, in physiologically-based pharmacokinetic (PBPK) modeling and simulations. John Wiley & Sons, Inc.; 2012. p. 407-421.
  • Oosterhuis, B, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol, 1991;32(5):569-572.
  • Hayward, RP, Greenwood, H, Hamer, J. Comparison of digoxin and medigoxin in normal subjects. Br J Clin Pharmacol. 1978;6(1): 81-86.
  • Greiner, B, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104(2):147-153.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.